Therapies & Progress

Esperion Therapeutics is focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C.

Esperion’s portfolio includes one product candidate in global Phase 3 clinical development, Bempedoic Acid (ETC-1002), and two early-stage product candidates, ESP41091¬†and ApoA-1 Mimetics.

Esperion owns the exclusive worldwide rights to all three compounds.

 

Esperion Portfolio

Esperion Portfolio Jan 2016